Bausch Health Announces $63 Million Acquisition of DURECT Corporation to Enhance Liver Disease Solutions

August 9, 2025 - 11:23

Bausch Health Companies Inc. has made a significant move in the healthcare sector by announcing a definitive agreement to acquire DURECT Corporation. This strategic acquisition, valued at approximately $63 million upfront, aims to bolster Bausch Health's portfolio in the treatment of liver diseases. The deal also includes potential sales milestone payments that could reach an additional $350 million, highlighting the company’s confidence in DURECT's innovative therapies.

The acquisition is expected to enhance Bausch Health's capabilities in addressing unmet medical needs within the liver disease treatment landscape. DURECT is known for its advanced drug delivery technologies and therapeutic solutions, which align with Bausch Health's mission to improve patient outcomes.

This acquisition comes at a pivotal time as Bausch Health continues to focus on expanding its product offerings and strengthening its position in the healthcare market. The company believes that integrating DURECT's expertise will accelerate the development of new treatments, ultimately benefiting patients suffering from liver-related conditions.